ArticleRespiration; international review of thoracic diseases2026
Pulmonary Hypertension in Patients with Moderate to Severe Hypersensitivity Pneumonitis.
Article in Respiration; international review of thoracic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypersensitivity pneumonitis (HP) is characterized by a complex immunological reaction of the lung that may lead to chronic interstitial lung disease (ILD). Pulmonary hypertension (PH) may aggravate the clinical picture. We aimed to assess the prevalence of PH in 2 independent cohorts including patients with moderate and severe HP.
methodsWe retrospectively analyzed the data of HP patients with severe ILD undergoing lung transplantation (cohort-1) and invited HP patients with mild disease participating at pulmonary rehabilitation for a prospective screening for PH (cohort-2). The presence of PH was assessed by both echocardiography and right heart catheterization (RHC).
resultsIn cohort-1 (n = 55, median age 57 [95% CI 52-60] years, 59% male, forced vital capacity [FVC] 37 [35-45] %predicted), echocardiographic systolic pulmonary arterial pressure (sPAP) was available in 31 patients and showed elevated values (53 [45-63] mm Hg). Sixteen patients had a high probability of PH (sPAP >50 mm Hg). RHC was performed based on clinical suspicion of PH or as part of the clinical assessment for transplantation in 21 patients, revealing a mean pulmonary arterial pressure (mPAP) of 28 (24-33) mm Hg and a pulmonary vascular resistance (PVR) of 2.8 (2.2-3.4) Wood units in this group; PH was confirmed in 15 patients (71% of those undergoing RHC, 27% of the total cohort). In cohort-2 (n = 96, median age 62 [60-65] years, 66% male, FVC 98 [95-104] % predicted), echocardiographic screening was available in 88 patients and showed upper-normal sPAP values (29 [28-31] mm Hg). One (1%) patient had a high probability of PH. Following noninvasive clinical assessment, RHC was performed in 13 patients with suspected PH. Hemodynamic measurements showed an mPAP of 19 (16-21) mm Hg and a PVR of 1.9 (1.7-2.8) Wood units in this group, and PH was confirmed in 5 patients (38% of those undergoing RHC, 5% of the total cohort). All 5 patients had a plausible alternative explanation for their PH.
conclusionPH is a frequent complication in patients with HP and severe ILD. In HP patients with mild disease, PH is uncommon and alternative causes should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.